| GC48303-5mg |
|
— |
β-hydroxy Pyruvic Acid (lithium salt hydrate)
|
0 |
— |
|
|
|
| GC48303-1mg |
|
— |
β-hydroxy Pyruvic Acid (lithium salt hydrate)
|
0 |
— |
|
|
|
| GC48301-5mg |
|
807631-10-3 |
β-hydroxy 2C-B (hydrochloride)
|
0 |
— |
|
|
|
| GC48301-1mg |
|
807631-10-3 |
β-hydroxy 2C-B (hydrochloride)
|
0 |
— |
|
|
|
| GC48300-1mg |
|
— |
β-Endorphin (human) (trifluoroacetate salt)
|
0 |
— |
|
|
|
| GC48300-500μg |
|
— |
β-Endorphin (human) (trifluoroacetate salt)
|
0 |
— |
|
|
|
| GC48299-50g |
|
13035-61-5 |
β-D-Ribofuranose 1,2,3,5-tetraacetate
|
0 |
— |
|
|
|
| GC48299-25g |
|
13035-61-5 |
β-D-Ribofuranose 1,2,3,5-tetraacetate
|
0 |
— |
|
|
|
| GC48299-10g |
|
13035-61-5 |
β-D-Ribofuranose 1,2,3,5-tetraacetate
|
0 |
— |
|
|
|
| GC48299-5g |
|
13035-61-5 |
β-D-Ribofuranose 1,2,3,5-tetraacetate
|
0 |
— |
|
|
|
| GC48298-100μg |
|
— |
β-Defensin-2 (human) (trifluoroacetate salt)
|
0 |
— |
|
|
|
| GC48297-100g |
|
68168-23-0 |
|
0 |
— |
|
|
|
| GC48297-50g |
|
68168-23-0 |
|
0 |
— |
|
|
|
| GC48297-25g |
|
68168-23-0 |
|
0 |
— |
|
|
|
| GC48296-1mg |
|
1781744-06-6 |
α-Pyrrolidinopentiophenone-d8 (hydrochloride)
|
0 |
— |
|
|
|
| GC48296-500μg |
|
1781744-06-6 |
α-Pyrrolidinopentiophenone-d8 (hydrochloride)
|
0 |
— |
|
|
|
| GC48295-5mg |
|
5485-65-4 |
α-Pyrrolidinopentiophenone (hydrochloride)
|
0 |
— |
|
|
|
| GC48295-1mg |
|
5485-65-4 |
α-Pyrrolidinopentiophenone (hydrochloride)
|
0 |
— |
|
|
|
| GC48294-5mg |
|
1803168-16-2 |
α-Pyrrolidinocyclohexanophenone (hydrochloride)
|
0 |
— |
|
|
|
| GC48294-1mg |
|
1803168-16-2 |
α-Pyrrolidinocyclohexanophenone (hydrochloride)
|
0 |
— |
|
|
|
